Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter open-label phase IV study of Hematoporphyrin Injection photodynamic therapy for superficial malignant tumors, precancerous lesions and port-wine stains
CTR20250747Phase 4Active
- Sponsor
- Huading Modern Biopharmaceutical
- Start
- Jan 2025
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of hemoporfin in cancer, Precancerous lesion of mucosa or skin, port-wine stain, bladder cancer, sponsored by Huading Modern Biopharmaceutical. Started Jan 2025; status: active.
02
Drugs
hemoporfin
03
Conditions
cancerPrecancerous lesion of mucosa or skinport-wine stainbladder cancer
Beyond the preview
Go deeper on CTR20250747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250747.